Leuject (Cladribine)

Cladribine is taken up by lymphocytes and phosphorylated to an active triphosphate that is incorporated into DNA. This incorporation causes DNA strand breaks and blocks repair, leading to apoptosis of rapidly dividing lymphocytes while sparing most other cell types, thereby reducing abnormal immune activity.

The dosing regimen for Leuject is determined by the prescribing physician based on the specific indication, patient weight, renal and hepatic function, and other clinical factors. The prescriber will set the dose and schedule according to the approved product labeling.

Safety of cladribine during pregnancy and lactation has not been fully established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To request Leuject, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

In hairy cell leukemia, cladribine is often preferred over older agents such as pentostatin because of higher remission rates. For multiple sclerosis, cladribine offers an oral‑free, intermittent dosing schedule compared with continuous infusion biologics, but clinicians weigh efficacy, safety profile, and patient preference when selecting therapy.

Leuject must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product is inadvertently exposed to temperatures outside this range, it should not be used.

Leuject is supplied as a sterile solution for subcutaneous injection. The injection is performed by a qualified healthcare professional, typically in a clinical setting, using aseptic technique. The dose and frequency are prescribed by the treating physician.

The most serious risks include severe or opportunistic infections due to profound lymphopenia, secondary malignancies, autoimmune hepatitis, and rare hypersensitivity reactions such as anaphylaxis. Patients should be monitored closely for signs of infection and liver dysfunction throughout therapy.

Leuject is contraindicated in patients with active severe infections, known hypersensitivity to cladribine or any excipients, and in pregnant women unless the benefit outweighs the risk. Caution is also advised for individuals with severe immunodeficiency or uncontrolled organ dysfunction.